Monday, September 23, 2013

Roche-Genentech Profitability Linked to Oncology Portfolio

Convenience advantages of Roche’s (RHHBY-$65.84) new injectable version of Herceptin could outweigh the lower price advantage of a biosimilar trastuzmab, especially in a metastatic maintenance setting: The subcutaneous form of Herceptin is a ready-to-use liquid formulation that is administered as a 600 mg/5 ml fixed dose every three weeks, simplifying healthcare procedures by removing the need for reconstitution or dose calculation according to the body weight of the individual. Timesaving advantages cuts the treatment time down to just two to five minutes, from 30 to 90 minutes to administer the drug intravenously.



Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

1 comment:

Howard Gibson said...

the next big drug is Lemtrada for MS.

http://med-editing.blogspot.com/2013/09/lemtrada-new-drug-for-multiple-sclerosis.html